Prognostické markery přežívání u pacientů s duktálním adenokarcinomem pankreatu

Title in English Prognostic markers for survival in patients with pancreatic ductal adenocarcinoma.

EID Michal TUČEK Štěpán KUNOVSKÝ Lumír

Year of publication 2021
Type Article in Periodical
Magazine / Source Onkologická Revue
MU Faculty or unit

Faculty of Medicine

Keywords pancreatic cancer; prognosis; markers; microRNA
Description The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing and mortality is still high. It has already been shown that PDAC is not a single disease but a very heterogeneous malignancy. Despite increasing knowledge, no major breakthrough in therapy has been observed in the last 30 years that would lead to long-term survival. An exception is an intensive regimen with a triplet of cytostatics - 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRINOX), which in adjuvant therapy achieves a median overall survival of 54.4 months and a median relapse-free survival of 21.6 months. However, it should be noted that in the PRODIGE 24 study, the entry criteria were strict and the population was heavily selected. In real practice, this intensive regimen is not suitable for all. However, there is a subpopulation of patients who survive for a long time with a diagnosis of PDAC. Clinical markers are already known that can help to estimate the prognosis of the patient at baseline. In addition to these, prognostic factors at the molecular level have recently been described and are likely to play an important role in the future. In this article, we focus on clinical, histopathological and molecular prognostic factors that may be useful in prognostic stratification.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info